肺癌作为全球死亡率最高的恶性肿瘤,严重威胁人类健康.近10年来,随着精准医学时代的到来,肺癌治疗格局已发生翻天覆地的变化.多项围术期免疫或靶向治疗相关的临床研究的公布让更多早期非小细胞肺癌(non-small-cell lung cancer,NSCLC)患者有望实现肿瘤"治愈".此外,免疫治疗及靶向治疗也让更多晚期NSCLC患者有望实现"慢病化".多种新型药物的研发,如抗体-药物偶联物(antibody-drug conjugate,ADC)、免疫双抗及肿瘤疫苗等百花齐放,进一步提高了抗肿瘤治疗疗效.本文将对近10年肺癌内科治疗领域的重要研究进行回顾,并根据目前治疗现状探讨未来发展方向.
Lung cancer remains the leading cause of cancer-related death,posing a serious threat to human health.Over the past decade,with the advent of the era of precision medicine,the landscape of lung cancer treatment has dramatically changed.A series of clinical trials related to perioperative immunotherapy or targeted therapy help to cure early-stage non-small-cell lung cancer(NSCLC).The application of immunotherapy and targeted therapy provides opportunities for patients with advanced NSCLC to achieve long-term survival.Addition-ally,a variety of new drugs,such as antibody-drug conjugates(ADCs),immune bispecific antibodies,and tumor vaccines,are expected to enhance the anti-tumor effectiveness.This article reviews important clinical trials in the field of lung cancer medical treatment over the past decade and discusses future directions based on the current treatment landscape.
陈薪如;周彩存
同济大学附属上海市肺科医院肿瘤科,上海 200433同济大学附属东方医院肿瘤科,上海 200123
肺癌;靶向治疗;免疫治疗
lung cancer;targeted therapy;immunotherapy
《实用肿瘤杂志》 2024 (003)
209-218 / 10
10.13267/j.cnki.syzlzz.2024.033
评论